GDNF Gene Therapy for Parkinson's Disease

Running, not enrolling · Phase 1

Conditions studied: Parkinson's Disease

In brief

The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.

Key facts

Study ID

NCT04167540

Run by

Brain Neurotherapy Bio, Inc.

People needed

11

Starts

2020-04-01

Expected to finish

2027-06-01

Last updated by the study team

2025-09-19

Who can join

Age: 35 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of California Irvine — Irvine, California, United States
• University of California San Francisco — San Francisco, California, United States
• The Ohio State University Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.